EET is now standard of care and endorsed by societal guidelines for the treatment of
Barrett's oesophagus related neoplasia. Future studies should focus on risk stratification …

Over the past few decades, the rates of esophageal adenocarcinoma (EAC) in the USA
continue to increase, particularly in adults≥ 65 years old (Fig. 1)[1]. Barrett's esophagus …

Aims Gastro-esophageal reflux disease (GERD) is a common, chronic gastrointestinal
condition characterized by heartburn, chest pain, regurgitation, and bloating. The current …

Background Esophageal adenocarcinoma has a very poor prognosis unless detected early.
The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a …

Background and study aims Radiofrequency ablation (RFA) for dysplastic Barrett's
esophagus (BE) has resulted in a paradigm shift in the management of BE. Despite …

Introduction: One of the most prevalent conditions in Western societies is gastroesophageal
reflux disease (GERD). In Switzerland, the standard treatment for GERD is proton pump …

Barrett's oesophagus is the only known precursor to oesophageal adenocarcinoma (OAC).
Although guidelines on the screening and surveillance exist in Barrett's oesophagus, the …

Introduction The standard treatment for gastroesophageal reflux disease (GERD) is proton
pump inhibitors (PPIs). In selected cases, Nissen fundoplication is offered as a surgical …

Endoscopic eradication therapy using radiofrequency ablation (RFA) is considered an
acceptable alternative to surveillance monitoring for Barrett's esophagus with low-grade …

Background and Aim Surveillance of non-dysplastic Barrett's esophagus (BE) is
recommended to identify progression to dysplasia; however, the most cost-effective strategy …